Compare Amgen, Inc. (AMGN) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Oracle Corporation — how do they compare? Amgen, Inc. trades at $359.22 (market cap $196.12B), while Oracle Corporation trades at $136.07 (market cap $405.11B). The key difference: Oracle Corporation is far larger — about 2.1× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | ORCL | |
|---|---|---|
Market Cap | $196.12B | $405.11B |
Sector | Health | Technology |
52-Week High | $388.16 | $328.33 |
52-Week Low | $271.18 | $136.39 |
Enterprise Value | $241.41B | $534.36B |
Dividend Yield | 2.77% | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Oracle Corporation (ORCL) trades at $140.68, down 2.49% today, amid mixed technical signals with a bearish overall trend. Fundamentally, the company shows strong profitability with 25.37% net income margin and consistent earnings beats in recent quarters. Revenue growth continues with $57.4B in FY2025, while analyst consensus remains bullish with a $259 price target. Recent news highlights Oracle's positioning in AI infrastructure and partnership developments with OpenAI.
Oracle presents a compelling investment case with strong fundamentals and AI growth potential, though technical weakness and high valuation metrics warrant caution. The stock offers upside to analyst targets but faces execution risks in competitive cloud markets and substantial debt levels that could pressure returns if interest rates remain elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
